LONDON, Nov 22 (Reuters) – U.S. officials have given a green
light for two clinical trials testing AstraZeneca’s
cancer immunotherapy drug durvalumab in head and neck cancer to
resume recruiting…
The post U.S. FDA lifts hold on AstraZeneca head and neck cancer trials appeared first on NASDAQ.